[EN] NOVEL PYRIMIDINE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS DE PYRIMIDINE
申请人:CHEMILIA AB
公开号:WO2012127032A1
公开(公告)日:2012-09-27
The invention provides novel pyrimidine derivatives of formula (I), methods of preparing such compounds, pharmaceutical compositions containing such compounds, and methods for using such compounds in treatment of diseases including cancer; wherein R1-R11, Z, and Y are as defined in the specification.
[EN] FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERARY<br/>[FR] DIAMIDES IMIDODICARBONIMIDIQUES LIÉS À UN ALKYLÈNE BICYCLIQUE FUSIONNÉ, PROCÉDÉS DE SYNTHÈSE ET UTILISATIONS DANS UNE THÉRAPIE
申请人:NOVATARG INC
公开号:WO2018106907A1
公开(公告)日:2018-06-14
The present invention provides novel fused bicyclic alkylene linked imidodicarbonimidic diamides. In particular, described herein are N-[2-(indol-3- yl)alkylene]-linked imidodicarbonimidic diamides and N-[2-(pyrrolopyridin-3- yl)alkylene]-linked imidodicarbonimidic diamides (compound of formula (I) or formula (II)), and uses therefor. The compounds of the present invention are believed to be organic cation transporter selective compounds, useful for the treatment of diseases and conditions caused by reduced activity of 5' adenosine monophosphate-activated protein kinase (AMPK).
[EN] N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR<br/>[FR] N-(2-ARYLETHYL)BENZYLAMINES UTILISEES EN TANT QU'ANTAGONISTES DU RECEPTEUR 5-HT6
申请人:LILLY CO ELI
公开号:WO2002078693A2
公开(公告)日:2002-10-10
The present invention provides compounds of formula (I), which are antagonists of the 5-HT6 receptor.
本发明提供了式(I)的化合物,它们是5-HT6受体的拮抗剂。
N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor
申请人:Chen Zhaogen
公开号:US20060009511A9
公开(公告)日:2006-01-12
The present invention provides compounds of formula (I), which are antagonists of the 5-HT
6
receptor.
本发明提供了式(I)的化合物,它们是5-HT6受体的拮抗剂。
N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR
申请人:Chen Zhaogen
公开号:US20070099909A1
公开(公告)日:2007-05-03
The present invention provides compounds of formula (I), which are antagonists of the 5-HT
6
receptor.